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Abstract
Background Magnesium salts bind dietary phos-
phorus, but their use in renal patients is limited due to
their potential for causing side effects. The aim of
this study was to evaluate the efﬁcacy and safety of
magnesium carbonate (MgCO3) as a phosphate-
binder in hemodialysis patients.
Methods Forty-six stable hemodialysis patients
were randomly allocated to receive either MgCO3
(n = 25) or calcium carbonate (CaCO3), (n = 21) for
6 months. The concentration of Mg in the dialysate
bath was 0.30 mmol/l in the MgCO3 group and
0.48 mmol/l in the CaCO3 group.
Results Only two of 25 patients (8%) discontinued
ingestion of MgCO3 due to complications: one (4%)
because of persistent diarrhea, and the other (4%)
because of recurrent hypermagnesemia. In the MgCO3
and CaCO3 groups, respectively, time-averaged
(months1–6)serumconcentrationswere:phosphate(P),
5.47 vs. 5.29 mg/dl, P = ns; Ca, 9.13 vs. 9.60 mg/dl,
P\0.001; Ca 9 P product, 50.35 vs. 50.70 (mg/dl)
2,
P = ns; Mg, 2.57 vs. 2.41 mg/dl, P = ns; intact
parathyroid hormone (iPTH), 285 vs. 235 pg/ml,
P\0.01. At month 6, iPTH levels did not differ
betweengroups:251vs.212 pg/ml,P = ns.Atmonth6
the percentages of patients with serum levels of phos-
phate, Ca 9 P product and iPTH that fell within the
Kidney Disease Outcomes Quality Initiative (K/DOQI)
guidelines were similar in both groups, whereas more
patientsintheMgCO3group(17/23;73.91%)thaninthe
CaCO3 group (5/20, 25%) had serum Ca levels that fell
within these guidelines, with the difference being
signiﬁcant at P\0.01.
Conclusion Our study shows that MgCO3 adminis-
tered for a period of 6 months is an effective and
inexpensiveagenttocontrolserumphosphatelevelsin
hemodialysis patients. The administration of MgCO3
in combination with a low dialysate Mg concentration
avoids the risk of severe hypermagnesemia.
Keywords End-stage renal disease  Hemodialysis 
Magnesium carbonate  Phosphate-binders
Introduction
Normalization of the serum phosphate level is the
cornerstone of medical protocols aimed at preventing
and treating secondary hyperparathyroidism. More-
over, it has been shown that elevated serum levels of
phosphateandthecalcium–phosphateproduct(Ca 9 P)
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DOI 10.1007/s11255-007-9300-0play an important role in the development of
extraosseous calciﬁcations and are associated with
increased mortality in hemodialysis patients [1, 2].
The ingestion of phosphate-binding agents in con-
junction with dietary phosphate restriction and its
adequate removal by dialysis are the cornerstones of
serum phosphate control in end-stage renal disease
(ESRD) patients. However, four decades after the
introduction of chronic hemodialysis in early 1960s,
we have not yet found the ideal phosphate binder(s)
in terms of combined efﬁcacy, safety and low cost.
Aluminum and calcium salts and non-aluminum and
non-calcium agents, such as sevelamer and lanthanum
carbonate, all have advantages and disadvantages [3].
Magnesium-containing agents are aluminum- and
calcium-free and are inexpensive phosphate-binders
and, to date, their potential has not been explored
extensively. In studies involving small series of both
hemodialysis and peritoneal dialysis patients, magne-
sium carbonate (MgCO3) and magnesium hydroxide
[Mg(OH)2] have been administered either alone or in
combination with calcium salts with good results [4–
10]. However, these compounds are not widely used
in ESRD patients because nephrologists have an
inordinate fear of hypermagnesemia and the belief
that Mg administration frequently is accompanied by
gastrointestinal disorders.
We carried out this study in hemodialysis patients
to evaluate the efﬁcacy and safety of MgCO3 as a
phosphate-binder when given with a concurrent low
dialysate magnesium solution. The control of serum
phosphate in the two groups of patients was the
primary outcome, while secondary outcomes were
changes in serum calcium, magnesium, Ca 9 P and
PTH levels and changes in bowel movements.
Subjects and methods
Patients and study design
Stable ESRD patients on maintenance hemodialysis
in our renal unit participated in the study. The
protocol of this project was approved by the Ethics
Committee of the hospital. Exclusion criteria were:
age\18 years, hemodialysis for less than 6 months,
psychiatric or other disorders leading to non-compli-
ance, unlikeliness to continue hemodialysis for more
than 6 months in the same facility, critical illness at
the time of recruitment, previous parathyroidectomy,
severe hyperparathyroidism [serum intact parathyroid
hormone (iPTH) [ 500 pg/ml], normal serum phos-
phate (\5.5 mg/dl) without phosphate-binders,
diseases resulting in diarrhea and the lack of
informed consent. A total of 54 patients met the
criteria and were approached for enrolment. The
inclusion period lasted 2 months, between March 2
and April 29, 2006. Enrolled patients signed an
informed consent and thereafter entered a 4-week
washout period during which we withdrew all
phosphate-binders as well as vitamin D medications.
After the washout phase, three patients were removed
because they had serum phosphate levels lower than
5.8 mg/dl; the remaining 51 patients were allocated
to receive either MgCO3 tablets (MgCO3 group) or
calcium carbonate tablets (CaCO3 group) for
6 months. We chose CaCO3 instead of calcium
acetate because the latter is not commercially avail-
able in Greece. Four patients did not agree to
consume MgCO3 but did agree to participate by
taking their standard binder of CaCO3; we allocated
these patients to the CaCO3 group, whereas the
remainder of the patients were randomly allocated
with a ratio 1:1 to either the CaCO3 (21 randomly
assigned patients plus 4 = 25 patients) or to the
MgCO3 (26) group. Each MgCO3 tablet contained
250 mg MgCO3, which is equivalent to 71 mg of
elemental magnesium, and each CaCO3 tablet con-
tained 420 mg of CaCO3 equivalent to 168 mg of
elemental calcium. All patients were on the same
standard dialysis schedule (three times weekly 9 4
h), and in all of the patients the delivered dose of
hemodialysis, as calculated by applying the single
pool Kt/Vurea index using the second-generation
formula of Daugirdas [11],, was C1.35. In both
groups, calcium concentration in the dialysate bath
was 1.50 mmol/l, whereas magnesium concentration
was 0.48 mmol/l in the CaCO3 group and 0.30 mmol/l
in the MgCO3 group. The National Kidney Founda-
tion (NKF) suggests a bath calcium dialysate
concentration of 1.25 mmol/l (based on opinion, not
on evidence). We used a bath concentration
1.50 mmol/l because we wanted to avoid episodes
of hypocalcemia, particularly in the MgCO3 group.
The patients should be more susceptible to manifest
hypocalcemia since they did not receive vitamin D.
The starting dose of both phosphate-binders were
three tablets of MgCO3 or CaCO3 daily; the dose was
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123adjusted thereafter according to the serum phosphate
values: weekly for the ﬁrst month and then monthly.
The dosage of the study drug was increased to one or
two tablets per meal as required to achieve the target
of serum phosphate level B5.5 mg/dl. Based on our
clinical experience, to achieve adequate control of
serum phosphate we set the maximum daily dose of
CaCO3 to 3780 mg (nine tablets), which is equivalent
to 1512 mg of elemental calcium, and the maximum
daily dose of MgCO3 to 2250 mg (nine tablets), which
is equivalent to 639 mg of elemental magnesium.
Each patient’s full biochemical proﬁle was obtained at
baseline, then weekly during the ﬁrst month and
monthly thereafter. Parathyroid hormone was mea-
sured at baseline and then at monthly intervals. If a
patient developed hypercalcemia (serum Ca[10.5
mg/dl), the daily dose of CaCO3 was reduced by one
or two tablets. The same was done in patients with
severe hypermagnesemia, which is deﬁned as a serum
magnesium level [3.5 mg/dl. If severe hypermag-
nesemia persisted for more than 3 weeks, the
administration of MgCO3 was stopped, and the patient
was dropped from the study. No patient received
vitamin D or a calcimimetic agent during the study.
Serum total calcium values were corrected to the
serum albumin values.
Statistical analysis
The laboratory values were expressed as mean
[± one standard deviation (SD)].
Student’s two-tailed unpaired t test was used to
compare values between the two groups of patients at
baseline and at 6 months. We used repeated measures
of analysis of variance (repeated ANOVA method) to
test for differences between the two treatment groups
in average values of calcium, phosphate, Ca 9 P,
magnesium, alkaline phosphatase (ALP) and PTH
over time (time-averaged mean value differences).
The chi-square test was applied to determine differ-
ences in the prevalence of laboratory data.
Signiﬁcance was set at a P level of\0.05.
Results
Of the 26 patients enrolled in the MgCO3 group, one
dropped out due to non-compliance. Of the remaining
25 patients, two (8%) discontinued ingestion of
MgCO3 and dropped out: one (4%) because of
persistent diarrhea, and one (4%) because of recurrent
hypermagnesemia. Of the 25 patients in the CaCO3
group; ﬁve were removed from the study (two
received a kidney transplant, one died (pneumonia),
one suffered a stroke and was unable to swallow
tablets and one moved to another hospital). The use
of phosphate-binders and vitamin D by the patients
before the washout period is given in Table 1.
Patients’ mean serum values at baseline and at the
end of the follow-up period are shown in Tables 2
and 3. The monthly follow-up of the mean biochem-
ical parameters are shown in Figs. 1–4. The mean
Kt/Vurea was 1.379 ± 0.026 in the MgCO3 and
1.381 ± 0.027 in the CaCO3 group.
Table 1 Patients’ data in terms of the use of phosphate-
binders and vitamin D before the washout period
MgCO3 group
(n = 25)
CaCO3 group
(n = 21)
Vitamin D 11/25 8/21
Phosphate binders 25/25 21/21
CaCO3 19 16
Sevelamer 2 4
CaCO3 + sevelamer 4 1
Table 2 Mean serum values at baseline
MgCO3
group
CaCO3
group
P value
(t test)
Age (years) 63.23 65.32 P = ns
SD 12.19 11.68
Calcium (mg/dl)
a 9.42 9.14 P = ns
SD 0.54 0.43
Phosphorous (mg/dl) 6.63 6.58 P = ns
SD 0.86 0.88
Ca 9 P product (mg/dl)
2 62.62 60.08 P = ns
SD 10.36 8.35
Magnesium (mg/dl) 2.38 2.36 P = ns
SD 0.28 0.29
ALP (IU/l) 76 86 P = ns
SD 37 35
Intact PTH (pg/ml) 316 296 P = ns
SD 182 157
SD, Standard deviation; ALP, alkaline phosphatase; PTH,
parathyroid hormone; ns, not signiﬁcant
a Serum total calcium level corrected to serum albumin
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123The mean daily dose of CaCO3 was 6.76 tablets
(range 3–9) containing a total of 2839 mg (range
1260–3780) of CaCO3, which is equivalent to
1136 mg of elemental calcium (range 504–1512 mg)
The mean daily dose of MgCO3 was 6.21 tablets
(range 3–9) containing a total of 1552 mg (range 750–
2,250) of MgCO3, which is equivalent to 441 mg of
elemental magnesium (range 213–639 mg). A Shap-
iro–Wilk test did not indicate any evidence against the
normality assumption for the distribution of calcium,
phosphate, Ca 9 P, magnesium, ALP and PTH levels
within the two groups (CaCO3 and MgCO3) at any
time period during the follow-up. The signiﬁcance
level for the normality tests was set to a = 0.001.
Average values of the biochemical data during
months 1–6 are shown in Table 4. The initial mean
serumphosphatelevelswere6.63 mg/dlintheMgCO3
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Table 3 Mean values at 6 months
MgCO3
group
CaCO3
group
P value
(t test)
Calcium (mg/dl)
a 8.97 9.72 t = 2.16
SD 0.57 0.42 P\0.05
Phosphorous (mg/dl) 5.12 5.28 t = 0.49
SD 0.70 0.74 P = NS
Ca 9 P product (mg/dl)
2 46.04 51.38 t = 0.30
SD 7.65 7.75 P = NS
Magnesium (mg/dl) 2.59 2.40 t = 1.59
SD 0.43 0.41 P = NS
ALP (IU/l) 89 84 t = 0.46
SD 28 26 P = NS
Intact PTH (pg/ml) 251 212 t = 0.42
SD 118 198 P = NS
a Serum total calcium corrected to serum albumin
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123group and 6.58 mg/dl in the CaCO3 group (P = ns),
while at the end of the study serum phosphate values
were 5.13 and 5.26 mg/dl in the MgCO3 and CaCO3
groups respectively (P = ns; Tables 2, 3). Time-
averaged mean serum phosphate values were
5.47 mg/dl in the MgCO3 group and 5.29 mg/dl in
the CaCO3group (P = ns;Table 4). Serum phosphate
levels decreased by 23% in the MgCO3 group and by
19% in the CaCO3 group (P = ns). At the end of the
study 17 of 23 (74%) patients in the MgCO3 and 13 of
20 (65%) of the CaCO3 group, (v
2 = 0.10, P = ns)
had serum phosphate values within the range recom-
mended by the Kidney Disease Outcomes Quality
Initiative (K/DOQI) guidelines (upper threshold of
5.5 mg/dl) (Table 5).
Mean serum Ca values at baseline were 9.42 mg/dl
in the MgCO3 group and 9.14 mg/dl in the CaCO3
group (P = ns) (Table 2). Time-averaged mean
serum values were 9.13 mg/dl in the MgCO3 group
and 9.60 in the CaCO3 group (P\0.001) (Table 4).
At 6 months, these values were 8.97 and 9.72 mg/dl,
respectively (P\0.05) (Table 2). Seventeen patients
(17/23; 74%) who received MgCO3 and only 5/20
(25%) of those on CaCO3 had serum Ca values within
the K/DQOI guidelines ( v
2 = 8.42, P\0.01)
(Table 5). We encountered six episodes of hypercal-
cemia, deﬁned as a serum calcium level[10.5 mg/dl,
in the CaCO3 group in comparison to one episode in
the MgCO3 group.
The two groups of patients had nearly equal values
of serum Ca 9 P product at the beginning, at the end
as well as during the period study (Tables 2–4), with
the MgCO3 group having62.6 mg
2/dl
2and the CaCO3
group having 60.1 mg
2/dl
2 (P = ns) (Table 1). Mean
levels of Ca 9 P during months 1–6 of the follow-up
were similar – 50.35 mg
2/dl
2 in the MgCo3 group and
50.70 mg
2/dl
2 in the CaCo3 group (P = ns) (Table 4);
at the end of the study, the corresponding values were
46.0 and 51.4 mg
2/dl
2 (P = ns) (Table 3), whereas
20/23 (87%) and 14/20 (70%) patients, respectively,
had Ca 9 P product below the upper limits of K/
DQOI recommendations (P = ns) (Table 5).
Starting mean levels of serum iPTH were similar
in both groups – 316 ± 182 pg/ml in the MgCO3
group and 296 ± 157 pg/ml in the CaCO3 group
(P = ns) (normal range 10–65 pg/ml) (Table 2).
During the 6-month follow-up period, average iPTH
levels were signiﬁcantly higher in the MgCO3-treated
patients (285 pg/ml) than in those treated with
CaCO3 (231 pg/ml) (P\0.01) (Table 4). However,
at the end of the study, those levels did not differ
signiﬁcantly – 251 ± 118 and 212 ± 198 pg/ml,
respectively (P = ns) (Table 3). In terms of PTH
levels, there was no statistically signiﬁcant difference
between the CaCO3 group and the MgCO3 group – 29
versus 21%, respectively (v
2 = 0.11, P = ns). More-
over, ten of 23 (43%) patients in the MgCO3 group
and nine of 20 (45%) in the CaCO3 group had initial
levels of iPTH above 300 pg/ml; in three of these ten
patients (30%) of the MgCO3 group and ﬁve of the
nine (56%) of the CaCO3 group, the iPTH decreased
below 300 pg/ml [v
2 = 1.38, P = ns; 11/23 (48%)].
Eight of 20 patients (40%) in the CaCO3 group and
Table 4 Average serum values during months 1–6 of the
follow-up period
MgCO3
group
CaCO3
group
P value
(t test)
Calcium (mg/dl)
a 9.13 9.60 P\0.001
SD 0.53 0.45
Phosphorous (mg/dl) 5.47 5.29 P = ns
SD 0.81 0.93
Ca 9 P product (mg/dl)
2 50.35 50.70 P = ns
SD 7.75 8.07
Magnesium (mg/dl)
2 2.57 2.41 P = ns
SD 0.41 0.32
ALP (IU/l) 88 80 P = ns
SD 32 27
Intact PTH (pg/ml) 285 231 P\0.01
SD 161 177
a Serum total calcium corrected to serum albumin
Table 5 Patients with
laboratory values within the
Kidney Disease Outcomes
Quality Initiative (K/DOQI)
guideline range at 6 months
MgCO3 group (n, %) CaCO3 group (n,% ) v
2, P value
Calcium 17/23 (73.91) 5/20 (25) v
2 = 8.42, P\0.01
Phosphorous 17/23 (73.91) 13/20 (65) v
2 = 0.10, P = ns
Ca 9 P product 20/23 (86.95) 14/20 (70) v
2 = 0.99, P = ns
PTH 11/23 (47.82) 8/20 (40) v
2 = 0.79, P = ns
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123six of 23 patients (26%) in the MgCO3 group
(P = ns) had ﬁnal values of iPTH below 150 pg/
ml. The number of patients of both groups, patients
who received MgCO3, and eight of 20 (40%) patients
who received CaCO3 who had serum phosphorus,
calcium, Ca 9 P product and iPTH values at
6 months that fell within the range recommended
by the K/DOQI guidelines are shown in Table 5
(v
2 = 0.79, P = ns).
During the follow-up period the average serum Mg
levels were slightly – but not signiﬁcantly – higher in
the MgCO3 group than in the CaCO3 group: 2.57 vs.
2.41 mg/dl (P = ns) (Table 4). Similarly, at
6 months, these values were 2.59 and 2.40 mg/dl
(P = ns) (Table 3). One patient of the 25 (4%)
stopped taking MgCO3 because of recurrent high
levels of serum magnesium ([3.5 mg/dl, the upper
threshold according to our protocol). Two more
patients manifested a transient elevation of serum
magnesium – from 3.18 to 3.36 mg/dl. No patient in
the CaCO3 group had a serum magnesium[3 mg/dl.
Discussion
This is the ﬁrst study that compares MgCO3 with only
one other phosphate-binder in hemodialysis patients.
Our results show that MgCO3 administered for a
period of 6 months has a good phosphate-binding
ability, is well tolerated by most patients and is
accompanied by a low incidence of side effects.
O’Donovan et al. [4] described 28 patients on
hemodialysis who were given magnesium chloride in
placeoforalaluminumhydroxide.Thesepatientswere
also switched from a dialysate containing 0.85 mmol/l
magnesium to one not containing any magnesium at
all. After 24 months of treatment on this regimen,
serum phosphate was effectively controlled in these
patients. The researchers saw no evidence ofincreased
secondary hyperparathyroidism. Delmez et al. [5]
conducted a 10-week, prospective, randomized cross-
over study of 15 hemodialysis patients, who were on
MgCO3 with a dialysate magnesium concentration of
0.25 mmol/l; with this regimen, these investigators
were able to reduce the CaCO3 dose and use a higher
dose of calcitriol. Mean serum phosphate levels in the
patients were similar with the MgCO3/CaCO3 combi-
nation as with the CaCO3 treatment alone (5.7 ± 0.2
vs. 5.2 ± 0.2 mg/dl, respectively), and there were no
adverse gastrointestinal effects. Parsons et al. [6]
described 32 continuous cycling peritoneal dialysis
(CAPD) in patients who were dialyzed with magne-
sium-free dialysate and used a mixture of CaCO3 and
MgCO3 as a phosphate-binder for over 1 year. These
patients achieved satisfactory control of hyperpara-
thyroidism, with normal serum calcium, phosphorous
and magnesium concentrations. Other investigators
have also shownthat theuse ofmagnesium-containing
agents as phosphate-binders can provide effective
control of serum phosphate and hyperparathyroidism
and that serum magnesium levels remain within
acceptable ranges [7–10]. Spiegel et al. [12] recently
comparedaregimen ofMgCO3and CaCO3versus one
with calcium acetate and found that the two were
equally effective as phosphate-binders.
In our study, MgCO3 was well tolerated by most of
our patients – only two of the 25 patients (8%) of this
group were removed from the study, one for diarrhea
and the other for hypermagnesemia. A third patient
complained initially of mild diarrhea and abdominal
discomfort, but this resolved after the ﬁrst week. In
comparison, ﬁve patients in the CaCO3 arm com-
plained of constipation, but none dropped out of the
study.
Serum phosphate levels after the 4-week wash-out
period were 6.63 mg/dl in the MgCO3 group and
6.58 mg/dl in the CaCO3 group. These values are
lower than those reported by other investigators:
7.7 mg/dl by Qunibi et al. [13] in the CARE study,
7.4–7.7 mg/dl by Chertow et al. [14] in the Treat to
Goal study and 6.6–7.2 mg/dl by Asmus et al. [15].
However, in the recently presented preliminary
results of the CARE 2 study [16], patients’ mean
serum phosphate values were 6.5–6.6 mg/dl. Our
values may have been lower because our patients
adhered more closely to their diet, they were
receiving an adequate dose of hemodialysis or they
had neither marked hyperparathyroidism (siPTH
\500 pg/ml) nor did they receive vitamin D. The
Mediterranean type of diet consumed by our popu-
lation on the island of Crete is less likely to cause
hyperphosphatemia.
The serum phosphate level was reduced equally in
both groups, and after the second month of treatment
the mean values of serum phosphate in the two
groups were comparable. (Table 3; Fig. 1).
In terms of the biochemical ﬁndings, the main
difference between the two groups was the levels of
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123serum calcium. Hypercalcemia is the price one has to
pay for adequate phosphate-binding control with
calcium-containing binders; the absence of hypercal-
cemia is the major advantage of magnesium-based
phosphate-binders.
We observed that patients receiving MgCO3 were
more likely to have serumcalciumlevels within the K/
DQOI guidelines [17] than those on CaCO3. Both
groups of patients achieved a mean serum Ca 9 P
product of\55 mg
2/dl
2(Tables 3,4). Consequently, a
signiﬁcantproportionofpatientshadaCa 9 Pproduct
within the K/DQOI recommendations (Table 5).
The risk of severe hypermagnesemia is a major
concern when magnesium salts are administered to
hemodialysis patients. In such patients serum mag-
nesium levels depend chieﬂy on the dialysate
concentration of this ion, which standardly ranges
between 0.45 and 0.50 mmol/l. In the MgCO3 group
we used a low magnesium dialysate, 0.30 mmol/l,
and this enabled us to avoid extreme hypermagnese-
mia and keep serum magnesium levels within
acceptable ranges.
Clinical symptoms and ECG disorders due to
hypermagnesemia appear only when the level of
serum magnesium [4 mg/dl [18]. The ionized frac-
tion that represents approximately 60% of the total
serum magnesium is the biologically active form of
this element. Truttmann et al. [19] and Saha et al.
[20] recently demonstrated that the ionized fraction
of magnesium lower in HD patients than in individ-
uals with normal renal function; therefore, the
incidence of ‘real hypermagnesemia’ may be over-
estimated in these patients. Of note is that serum
magnesium accounts for approximately 1% of the
total body magnesium since it is mainly an intracel-
lular cation. Estimation of total body magnesium is
based on the determination of intracellular magne-
sium (IcMg) levels in skeletal muscles or in
peripheral lymphocytes [21]. Calculations on the
levels of magnesium in these tissues in uremic
patients have produced conﬂicting results, with
positive or neutral or even a negative correlation
with serum magnesium being found [22, 23].
Although we did not examine the consequences of
hypomagnesemia and high serum magnesium levels,
various studies have shown that hypomagnesemia
plays a signiﬁcant role in the pathogenesis of
cardiovascular diseases and that a high serum mag-
nesium level may retard the development and/or
acceleration of arterial atherosclerosis [24, 25].
Meema et al. [26] ﬁrst showed that ‘hypermagnese-
mia might be associated with retardation or
improvement of arterial calciﬁcations in peritoneal
dialysis patients’. Izawa et al. [27] described a
hemodialysis patient in whom soft-tissue calciﬁca-
tions resolved after treatment with a dialysate with a
high concentration of magnesium. Two studies by our
team [28, 29] clearly demonstrated that the absence
of mitral annular calciﬁcations and a thinner carotid
intima media thickness in hemodialysis patients both
correlated with higher levels of serum and intracel-
lular magnesium. In a previous study, we showed that
both intracellular and serum magnesium concentra-
tions were directly associated with 5-year survival in
94 hemodialysis patients of our unit [30].
One of the secondary objectives of the study was
to investigate if MgCO3 effectively controls serum
iPTH. Calcium carbonate was more effective than
MgCO3 in decreasing serum iPTH. In the MgCO3-
treated patients time-average mean values of iPTH
during months 1–6 were signiﬁcantly higher than in
those treated with CaCO3 (Table 4). However, the
ﬁnal levels of serum iPTH at 6 months did not differ
signiﬁcantly between the two groups. Furthermore, at
the end of 6 months, a slightly higher number of
patients (48%) in the MgCO3 group than in the
CaCO3 (40%) group achieved serum iPTH values in
the range of 150–300 pg/ml.
In the presence of almost equal serum P values in
the two groups, we hypothesize that the relatively
higher PTH reduction in the CaCO3 group was due to
the signiﬁcant higher concentration of serum calcium
in this group. On the other hand, high levels of serum
magnesium have a similar, but weaker, action in
suppressing PTH secretion [31]. Figure 4, which
shows the monthly follow-up of serum iPTH levels,
shows that the curve of the change in mean iPTH
values is different in the MgCO3-treated patients in
that the mean values increase during the ﬁrst month
of the treatment, subsequently falling (but slower
than in the CaCO3 group) and ﬁnally, in the sixth
month, they approach the mean iPTH values of the
CaCO3 group. We speculate that the shape of this
curve indicates that suppressive action of serum
magnesium on the parathyroid glands is weaker but
delayed compared to that of serum calcium. The
number of patient who had ﬁnal serum iPTH values of
\150 pg/ml, which could be associated with
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groups. However, the impact of the two regimens on
the patients’ bone turn over was not included in the
objectives of the study, so we did not obtain data
associated with bone metabolism markers.
Our experience suggests that a signiﬁcant propor-
tion of hemodialysis patients need more than one
agent to achieve a satisfactory phosphate-binding. In
such cases, MgCO3 could be if not the primary at
least the second constituent of the phosphate-binding
regimen, combined ideally with a calcium-containing
salt. An additional advantage is that MgCO3 is much
less expensive than the newest sevelamer HCL and
lanthanum carbonate.
The limitations of our study are: (1) it is a single-
center study, although this has also a number of
advantages; (2) the number of the participant patients
was not large, although it is one of the largest groups
reported to date; (3) the allocation of the patients to
the two regimens was only partially random; (4) the
relatively low starting serum phosphate level in
conjunction with the no vitamin D use means that
the patients were not typical of most HD patients; (5)
we did not obtain data on the patients’ bone
metabolism markers.
In conclusion, our study showed that MgCO3
administered for a period of 6 months is an effective
and inexpensive agent to control serum P levels in
hemodialysis patients. Gastrointestinal disorders due
to its use were minor, while its administration in
combination with a low dialysate magnesium concen-
tration reduces the risk of severe hypermagnesemia.
PatientstreatedwithMgCO3hadamildsuppressionof
PTH, an optimum regulation of Ca 9 P product,
relatively low serum calcium and no episodes of
hypercalcemia. We believe that this demonstration of
theeffectivenessofMgCO3tobindphosphatewarrants
further investigation in a larger group of patients.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction
in any medium, provided the original author(s) and source are
credited.
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